Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Solid Tumors
Filter by Topic
Bladder Cancer
Breast Cancer
Colon Cancer
Colorectal Cancer
Gastric Cancer
Genitourinary Cancers
GI Cancers
Gynecologic Cancer
Head and Neck Cancer
Liver Cancer
Lung Cancer
Melanoma
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Thyroid Cancer
Shorter Hypofractionated Therapy New Standard for Prostate Cancer
By
Phoebe Starr
Prostate Cancer
,
Solid Tumors
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
Men with intermediate-risk prostate cancer can safely undergo radiation administered in larger fractions for 4 weeks (moderate hypofractionation) as an alternative to conventional radiation administered for 8 weeks, according to the results of a randomized, controlled, noninferiority clinical trial presented at ASCO 2016.
Read Article
Is the Glass Half Empty or Half Full? First Study Compares Robotic-Assisted Surgery and Open Radical Prostatectomy
By
Alice Goodman
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
The first randomized trial to compare robotic-assisted prostatectomy with conventional open radical prostatectomy found no meaningful differences between these techniques in urinary and sexual function or in the rate of positive surgical margins in men with localized prostate cancer in the first 12 weeks after surgery (Yaxley JW, et al.
Lancet.
2016 Jul 26. Epub ahead of print).
Read Article
Extending Letrozole Therapy Beyond 5 Years in Early Breast Cancer Reduces Recurrence
By
Phoebe Starr
Breast Cancer
,
Solid Tumors
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
Extending aromatase inhibitor therapy with letrozole for an additional 5 years beyond standard treatment with letrozole improved disease-free survival (DFS) and reduced the rate of new contralateral breast cancer in postmenopausal women with estrogen receptor (ER)-positive breast cancer.
Read Article
Atezolizumab Could Be Start of “Seismic Shift” in Metastatic Bladder Cancer Therapy
By
Wayne Kuznar
Bladder Cancer
,
Solid Tumors
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
Atezolizumab (Tecentriq) shows promise as primary therapy in patients with cisplatin-ineligible, locally advanced metastatic urothelial (bladder) cancer, according to data from the IMvigor210 study presented at ASCO 2016.
Read Article
Cologuard: Stool DNA Test Performs Well in Community-Based Setting Among Medicare Beneficiaries
By
Charles Bankhead
Colorectal Cancer
,
Solid Tumors
July 2016, Vol 7, No 6
The multitarget stool DNA test, a noninvasive screening tool for colorectal cancer (CRC), demonstrated potential for identifying cancer and advanced adenomas in community-based individuals who had previously not followed national screening recommendations, reported Mark Prince, MD, MBA, Director of Gastroenterology, USMD Health System, Arlington, TX, at the 2016 American Association for Cancer Research annual meeting.
Read Article
Irreversible Electroporation Boosts Soft-Tissue Cancer Survival, but with Significant Morbidity and Cost
By
Rosemary Frei, MSc
Pancreatic Cancer
,
Solid Tumors
July 2016, Vol 7, No 6
A new article by a New York surgical team confirms that there is a survival benefit from an emerging therapy for difficult-to-treat soft-tissue tumors, but that it is not without a steep price for some patients.
Read Article
Nivolumab Monotherapy Prolongs Survival in Patients with Advanced Melanoma
By
Wayne Kuznar
Melanoma
,
Solid Tumors
June 2016, Vol 7, No 5
More than 33% of patients with heavily pretreated advanced melanoma are still alive at 5 years after starting nivolumab (Opdivo) monotherapy, reported F. Stephen Hodi, Jr, MD, Director of the Melanoma Center, Dana-Farber Cancer Institute, Boston, at the 2016 American Association for Cancer Research (AACR) meeting.
Read Article
Debating the Role of Intralesional Therapy in Melanoma
By
Walter Alexander
Melanoma
,
Solid Tumors
June 2016, Vol 7, No 5
“Intralesional therapy is here to stay,” said Sanjiv S. Agarwala, MD, Section Chief, Hematology/Oncology, St Luke’s University Health Network, Easton, PA, who moderated a debate on this topic at the recent
HemOnc Today
Melanoma and Cutaneous Malignancies meeting.
Read Article
Minor Changes in Systemic Therapy Recommendations in NCCN Breast Cancer Guideline
By
Wayne Kuznar
Breast Cancer
,
Solid Tumors
June 2016, Vol 7, No 5
Read Article
Early Results of Immunotherapy in Breast Cancer
By
Phoebe Starr
Breast Cancer
,
Solid Tumors
June 2016, Vol 7, No 5
Read Article
Page 6 of 16
1
2
3
4
5
6
7
8
9
10
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma